GLOBAL BARRETT’S ESOPHAGUS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024 - 2031)

Key Developments

• In November 2023, Phathom Pharmaceuticals, Inc., a biopharmaceutical company that focuses on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced  that the U.S. Food and Drug Administration (FDA) had approved VOQUEZNA (vonoprazan) tablets 10 mg and 20 mg, a novel potassium-competitive acid blocker (PCAB), as a new treatment for adults for the healing of all grades of Erosive Esophagitis, also known as Erosive GERD (gastroesophageal reflux disease), maintenance of healing of all grades of Erosive GERD, and relief of heartburn associated with Erosive GERD
• In March 2023, Hackensack Meridian JFK University Medical Center announced the launch of its new Gastroesophageal Reflux and Motility Program, which will provide expert diagnosis and treatment of gastroesophageal reflux disease, also known as GERD, and other related motility disorders that affect gastrointestinal muscles. GERD is characterized as nonerosive reflux disease (NERD), erosive esophagitis, and Barrett's esophagus.
• In January 2022, Dana-Farber Cancer Institute scientists published a study that demonstrated Barrett’s esophagus does not involve esophageal cells turning into intestinal cells, but stomach cells adopting some of the characteristics of intestinal cells. The second study, published in the current issue of Genes and Development, traces the series of molecular events by which this occurs.
• In March 2020, Cipla, a global pharmaceutical company, announced that it had received final approval for its Abbreviated New Drug Application (ANDA) for Esomeprazole for Oral Suspension 10mg, 20mg and 40mg from the United States Food and Drug Administration (US FDA). Cipla is the first company to file for the 10mg strength.